130,95 €
130,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
65 °P sammeln
130,95 €
130,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
65 °P sammeln
Als Download kaufen
130,95 €
inkl. MwSt.
Sofort per Download lieferbar
payback
65 °P sammeln
Jetzt verschenken
130,95 €
inkl. MwSt.
Sofort per Download lieferbar

Alle Infos zum eBook verschenken
payback
65 °P sammeln
  • Format: ePub

This book is intended to introduce the real medical problems and solutions by leading-edge researchers in engineering. If the readers in this growing research field can get hints or new ideas from this book, it is a great pleasure to us.

  • Geräte: eReader
  • ohne Kopierschutz
  • eBook Hilfe
  • Größe: 47.16MB
Produktbeschreibung
This book is intended to introduce the real medical problems and solutions by leading-edge researchers in engineering. If the readers in this growing research field can get hints or new ideas from this book, it is a great pleasure to us.


Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Autorenporträt
Akihiro Miyauchi is a professor at the Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Japan. He received his PhD from Tokyo Institute of Technology, Japan, in 1995. He worked for Hitachi Ltd from 1986 to 2017 and was a visiting scientist at the Massachusetts Institute of Technology from 1995 to 1996. Prof. Miyauchi's research interests are in semiconductor process, nanoimprint, and biomimetics.



Hiroyuki Kagechika
is a professor and director at the Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University. He received his PhD in pharmaceutical sciences from the University of Tokyo, Japan, in 1989. Prof. Kagechika's major research interest is in the development of functional organic molecules in the field of medicinal chemistry, chemical biology, and materials sciences. He has developed various novel bioactive compounds, including a drug for acute promyelocytic leukemia.